Journal
CURRENT ONCOLOGY
Volume 28, Issue 6, Pages 4317-4327Publisher
MDPI
DOI: 10.3390/curroncol28060367
Keywords
hepatocellular cancer; local therapy; TACE; SABR; systemic therapy; immunotherapy
Categories
Funding
- Pfizer
- Hoffmann-La Roche
- AstraZeneca Canada
- Roche
- Eisai
- Bristol Myers Squibb
- Merck Inc.
- Taiho Canada
Ask authors/readers for more resources
The Fifth Western Canadian Gastrointestinal Cancer Consensus Conference convened virtually on February 10, 2021. The conference aimed to address current issues in the management of hepatocellular cancer (HCC) and provided recommendations for the transition from local to systemic therapy and the optimal sequencing of systemic regimens for HCC.
The Western Canadian Gastrointestinal Cancer Consensus Conference (WC-5) convened virtually on 10 February 2021. The WC-5 is an interactive multidisciplinary conference attended by health care professionals from across Western Canada (British Columbia, Alberta, Saskatchewan, and Manitoba) who are involved in the care of patients with gastrointestinal cancer. Surgical, medical, and radiation oncologists; pathologists; radiologists; and allied health care professionals participated in presentation and discussion sessions for the purpose of developing the recommendations presented here. This consensus statement addresses current issues in the management of hepatocellular cancer (HCC). Recommendations have been made for the transition from local to systemic therapy and the optimal sequencing of systemic regimens in the management of HCC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available